Filing Analysis
Marpai, Inc. entered into securities purchase agreements for the offering of 12,100 shares of Series A Preferred Stock at $1,000 per share, totaling approximately $12.1 million in gross proceeds. The offering is led by the Mitchell Family Trust II and includes a board observer seat for Steve Mitchell.
🚩 Red Flags
- Potential dilution from the conversion of Series A Preferred Stock into Common Stock at $1.00 per share
- Most-Favored Nation (MFN) clauses provide existing investors with rights to amend terms if more favorable terms are issued later
- Mandatory registration requirement within 60 days may lead to future dilution via S-3/registration statement
📋 Key Facts
- Aggregate gross proceeds: ~$12,100,000
- Security type: Series A Preferred Stock (convertible to Common Stock)
- Conversion price: $1.00 per share
- Dividend: 8% dividend payable in Common Stock upon conversion or liquidity event
- Lead Investor: Mitchell Family Trust II (Steve Mitchell to serve as Board Observer for 2 years)
- Registration requirement: Company must file a registration statement within 60 days of closing
- Most-Favored Nation (MFN) treatment included for purchasers
Marpai, Inc. entered into an amendment to its purchase agreement with AXA S.A., restructuring payment obligations and imposing strict debt covenants. The amendment significantly alters the cash flow requirements related to the acquisition of Maestro Health, LLC.
🚩 Red Flags
- Significant increase in mandatory future cash outflows ($22.25M in 2029) creates high long-term liquidity pressure.
- Restrictive covenant: The company is prohibited from incurring any new debt, which severely limits financial flexibility and ability to raise capital via traditional lending.
- The restructuring implies the company was facing unsustainable debt service obligations previously.
📋 Key Facts
- Entered into Amendment No. 2 to Purchase Agreement (AXA Amendment) on July 16, 2026.
- Amends the original Membership Interest Purchase Agreement dated August 4, 2022.
- Payment terms for AXA amended: from now through Dec 31, 2026, payments of 35% of net proceeds are only required after $5 million in offering proceeds are received.
- Mandatory annual minimum payments to AXA: $0 (2026), $1,000,000 (2027), $5,000,000 (2028), and $22,250,969 (2029).
- The Company is prohibited from incurring any additional indebtedness beyond currently outstanding debt.
- Company claims the restructuring reduces debt service by $26.4 million through 2027.
Marpai, Inc. entered into a Securities Purchase Agreement on December 22, 2025, to issue 350,000 shares of Class A common stock and warrants for up to 700,000 shares at $1.00 per share. The company expects to raise approximately $350,000 in gross proceeds to be used for working capital.
🚩 Red Flags
- Significant potential dilution: The warrants allow for the issuance of up to 700,000 additional shares (2x the number of common shares issued).
- Small offering size ($350k) suggests limited runway and high reliance on external financing.
- Warrants are exercisable immediately, which can lead to immediate dilution upon exercise.
📋 Key Facts
- Date of Agreement: December 22, 2025
- Securities Issued: 350,000 shares of Class A common stock and warrants to purchase up to 700,000 shares of Common Stock.
- Price per unit (1 share + 2 warrants): $1.00.
- Warrant Exercise Price: $1.00 per share.
- Warrant Expiration: Three years from the date of issuance.
- Expected Gross Proceeds: Approximately $350,000.
- Use of Proceeds: Working capital and general corporate purposes.
Marpai, Inc. filed an 8-K to announce the release of selected financial information for the three and nine months ended September 30, 2025.
📋 Key Facts
- The filing is related to Item 2.02 (Results of Operations and Financial Condition).
- Selected financial information was released via press release on November 12, 2025.
- Reporting period covers the three and nine months ended September 30, 2025.
Marpai, Inc. entered into a Securities Purchase Agreement on November 7, 2025, to issue 3.85 million shares of Class A common stock and warrants for up to 7.7 million shares at $1.00 per unit. The offering is being conducted via private placement to insiders, including the COO, President, Chairman, and certain directors.
🚩 Red Flags
- Related-party transaction: The offering is being conducted with the company's COO/President, Chairman, and certain directors.
- Significant potential dilution: The issuance of warrants for up to 7.7 million shares represents a high level of future dilution relative to the current share count implied by the offering size.
📋 Key Facts
- Total gross proceeds expected: approximately $4 million.
- Securities issued: 3,850,000 shares of Class A common stock and warrants to purchase up to 7,700,000 shares.
- Price per unit (1 share + 2 warrants): $1.00.
- Warrant exercise price: $1.00 per share; exercisable for three years.
- Use of proceeds: Working capital and general corporate purposes.
- Closing date: Expected on or about November 7, 2025.
Marpai, Inc. filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation in Delaware. The amendment authorizes the issuance of 2,000,000 shares of 'blank-check' preferred stock.
🚩 Red Flags
- Authorization of 'blank-check' preferred stock can be used to facilitate rapid financing or implement anti-takeover measures (poison pills) without immediate shareholder vote for specific series terms.
📋 Key Facts
- The Company authorized 2,000,000 shares of preferred stock via a Certificate of Amendment filed on October 17, 2025.
- The new shares are 'blank-check preferred stock,' allowing the Board to determine series characteristics (voting, preferences, etc.) at its discretion.
- The amendment was approved by the Board on June 24, 2025, and by stockholders on August 27, 2025.
Marpai, Inc. entered into a Securities Purchase Agreement with HillCour Investment Fund, LLC, an entity controlled by CEO Damien Lamendola, for the private placement of 147,058 shares at $1.36 per share.
🚩 Red Flags
- Related-party transaction involving the CEO (Damien Lamendola)
- Private placement of equity to an insider/controlled entity
- Potential for dilution of existing shareholders
📋 Key Facts
- Date of agreement: September 30, 2025
- Counterparty: HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola)
- Security type: Class A common stock
- Quantity: 147,058 shares
- Price per share: $1.36
- Total transaction value: ~$199,958.88
Marpai, Inc. entered into a Securities Purchase Agreement on September 10, 2025, to issue 1,038,519 shares of Class A common stock via private placement at $1.0592 per share. The transaction involves significant related-party activity as the majority of the shares were purchased by an entity controlled by the CEO.
🚩 Red Flags
- Related-party transaction: The CEO's controlled entity (HillCour Investment Fund, LLC) is the primary purchaser of the new equity issuance.
- Potential dilution: Issuance of over 1 million shares in a private placement typically results in significant dilution for existing shareholders.
📋 Key Facts
- Date of agreement: September 10, 2025
- Total shares to be issued: 1,038,519 Class A common stock
- Purchase price per share: $1.0592
- HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola) purchased 896,903 shares
- The offering is being conducted via private placement under Section 4(a)(2) or Rule 506(b)
Marpai, Inc. announced the immediate resignation of its President, John Powers, due to personal health reasons. Dallas Scrip, currently the company's COO, has been appointed as the new President.
🚩 Red Flags
- Immediate departure of a key officer (President) can create temporary leadership instability.
📋 Key Facts
- John Powers resigned as President effective August 29, 2025.
- The resignation is attributed to personal health reasons and not a disagreement with company operations or policies.
- Mr. Powers will transition to a part-time advisory role as a Senior Consultant for sales and leadership teams.
- Dallas Scrip has been appointed President effective August 29, 2025.
- Mr. Scrip previously served as COO starting June 2, 2025, with prior executive experience at Centivo and ValueHealth Benefit Administrators.
Marpai, Inc. held its 2025 Annual Meeting of Stockholders on August 27, 2025. The filing reports the final voting results for director elections, ratification of auditors, and an amendment to the Certificate of Incorporation.
🚩 Red Flags
- Approval of blank-check preferred stock (Proposal No. 3) can be used for future financing or potentially dilutive measures, though common in micro-cap growth strategies.
📋 Key Facts
- Held 2025 Annual Meeting of Stockholders on August 27, 2025.
- Elected six directors: Damien Lamendola, Yaron Eitan, Sagiv Shiv, Colleen DiClaudio, Jennifer Calabrese, and Robert Pons.
- Ratified UHY LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Approved an amendment to the Certificate of Incorporation to authorize 2,000,000 shares of 'blank-check' preferred stock.
Marpai, Inc. filed an 8-K to announce the release of selected financial information for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing selected financial information.
- Company is an emerging growth company.
Marpai, Inc. entered into a Securities Purchase Agreement on July 29, 2025, to issue 603,640 shares of Class A common stock in a private placement at $1.0768 per share. Notably, the largest participant in this offering is HillCour Investment Fund, LLC, an entity controlled by the Company's CEO, Damien Lamendola.
🚩 Red Flags
- Related-party transaction: The CEO's controlled entity (HillCour) is the primary purchaser in this equity issuance.
- Potential dilution: Issuance of over 600k shares in a private placement may dilute existing shareholders.
📋 Key Facts
- Date of agreement: July 29, 2025
- Total shares issued: 603,640 Class A common stock
- Offering price: $1.0768 per share
- HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola) purchased 371,470 shares
- The offering was conducted via a private placement exempt from registration under Section 4(a)(2) or Rule 506(b)
Marpai, Inc. entered into a Securities Purchase Agreement to issue 130,208 shares of Class A common stock via private placement at $1.152 per share. Notably, one of the investors is HillCour Investment Fund, LLC, an entity controlled by the Company's CEO, Damien Lamendola.
🚩 Red Flags
- Related-party transaction: The CEO's controlled entity (HillCour) is a primary participant in the equity issuance.
- Potential dilution for existing shareholders through private placement of unregistered securities.
📋 Key Facts
- Date of agreement: July 17, 2024 (Note: Filing date says 2025, but text refers to 2024/2025 discrepancy).
- Total shares issued: 130,208 Class A common stock.
- Price per share: $1.152.
- HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola) purchased 86,805 shares.
- The offering was conducted via private placement under Section 4(a)(2) and/or Rule 506(b).
- Total proceeds from the sale: $150,100 (calculated as 130,208 * $1.152).
Marpai, Inc. filed an 8-K to announce the release of selected financial information for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing selected financial information.
- Company is an emerging growth company.
Marpai, Inc. announced the appointment of Dallas Scrip as Chief Operating Officer, effective June 2, 2025. The appointment includes a base salary of $250,000 and performance-based equity incentives tied to profitability and revenue milestones.
🚩 Red Flags
- Performance-based bonuses are heavily tied to aggressive revenue and net income targets, which may indicate management pressure to hit specific growth metrics.
📋 Key Facts
- Dallas Scrip appointed as COO, effective June 2, 2025.
- Annual base salary set at $250,000.
- 2025 incentive bonus of up to $125,000 contingent on the Company being profitable by fiscal year-end.
- 2026 performance bonuses tied to specific revenue ($50M-$100M) and net income ($5M-$7M) targets.
- Equity compensation includes 300,000 RSUs vesting over three years (100k per year).
- Immediate vesting of an additional 100,000 RSUs upon reaching $5 million in unadjusted EBITDA for a full fiscal year.
Marpai, Inc. issued a press release containing selected financial information for the three months and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 26, 2025
- Reporting period: Three months and year ended December 31, 2024
- The filing is a standard disclosure of selected financial results via press release (Exhibit 99.1).
Marpai, Inc. entered into a Debt Reduction Agreement with AXA S.A. on January 31, 2025. The agreement reduces the Company's total debt obligation by $3 million in aggregate.
🚩 Red Flags
- Debt reduction of this nature often suggests a previous high-leverage position or restructuring necessity common in distressed micro-caps.
📋 Key Facts
- The parties executed a 'Debt Reduction Agreement' on January 31, 2025.
- Total debt reduction amount is $3,000,000 in the aggregate.
- Reduction was triggered by three conditions: (i) largest shareholder contributed at least $3M in equity; (ii) Company maintained a listing on an agreed-upon nationally recognized exchange; and (iii) timely payments were made between Feb 29, 2024, and April 15, 2024.
- The agreement amends the original Membership Interest Purchase Agreement dated August 4, 2022.
Marpai, Inc. has amended its existing Securities Purchase Agreement to issue additional Senior Secured Convertible Debentures totaling up to $5,376,000 in principal for a purchase price of $5,000,000. The transaction includes personal guarantees from the CEO and real estate collateral.
🚩 Red Flags
- High level of leverage: The company is adding significant debt ($5.37M) to an existing $11.83M obligation.
- Personal Guarantees: CEO Damien Lamendola and his controlled entity (Hillcour Holding, LLC) have personally guaranteed the obligations.
- Collateralization: Debt is secured by first and second priority liens on real property owned by affiliates.
- Escrowed funds: $3M of the $5M investment is contingent upon meeting specific terms/conditions.
📋 Key Facts
- Amendment to an existing April 15, 2024 agreement with JGB Collateral LLC.
- Additional investment amount: up to $5,376,000 in principal for a total price of $5,000,000.
- $2,000,000 was delivered at closing; $3,000,000 is held in escrow pending certain conditions.
- The conversion feature from the original investment does not apply to these new debentures.
- Security includes first and second priority liens on certain real property owned by affiliates.
Marpai, Inc. entered into a Securities Purchase Agreement on December 5, 2024, to conduct a private placement of common stock totaling approximately $700,000. The offering is being conducted primarily with company insiders.
🚩 Red Flags
- Related-party transactions: The offering is heavily weighted toward company insiders (Chairman, CFO, and President).
- Micro-cap financing: Small dollar amount ($700k) suggests limited liquidity runway or urgent need for working capital.
📋 Key Facts
- Total aggregate shares to be issued: 621,194 shares of Class A common stock.
- Offering price per share: $1.13.
- Total transaction value: Approximately $700,000 (based on press release title).
- Investors include Chairman Yaron Eitan (110,619 shares), CFO Steve Johnson (5,000 shares), and President/COO John Powers (10,000 shares).
- The securities are being issued under exemptions from registration (Section 4(a)(2) or Rule 506(b)).
Marpai, Inc. issued an 8-K to release selected financial information for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 11, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing selected financial information.
Marpai, Inc. entered into a Securities Purchase Agreement on August 28, 2024, to issue 2,702,702 shares of Class A common stock at $0.481 per share. Notably, one of the two investors is HillCour Investment Fund, LLC, an entity controlled by the Company's CEO, Damien Lamendola.
🚩 Red Flags
- Related-party transaction: The CEO (Damien Lamendola) controls one of the two primary investors in this equity issuance.
- Potential dilution: Issuance of over 2.7 million shares into a micro-cap company can significantly dilute existing shareholders.
📋 Key Facts
- Date of agreement: August 28, 2024
- Total shares to be issued: 2,702,702 Class A common stock
- Purchase price per share: $0.481 (based on the closing bid price on OTCQX)
- HillCour Investment Fund, LLC purchased 1,351,351 shares
- The offering is a private placement exempt from registration under Section 4(a)(2) or Rule 506(b).
Marpai, Inc. issued a press release containing selected financial information for the three and six months ended June 30, 2024.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Three and six months ended June 30, 2024
- The filing is an Item 2.02 disclosure regarding results of operations and financial condition.
- Company is an emerging growth company.
Marpai, Inc. has partially redeemed $5 million of its previously issued Senior Secured Convertible Debentures. This reduces the total outstanding principal amount from $11,830,000 to $6,830,000.
🚩 Red Flags
- High debt load relative to micro-cap status ($6.8M remaining in senior secured convertible debentures).
📋 Key Facts
- The redemption was effective as of June 21, 2024.
- Original aggregate principal amount: $11,830,000.
- Amount redeemed: $5,000,000.
- Remaining aggregate principal amount: $6,830,000.
- The redemption was made pursuant to an optional redemption provision in a Securities Purchase Agreement dated April 17, 2024.
Marpai, Inc. has announced its intention to withdraw from the Nasdaq hearings process and transition its Class A common shares from the Nasdaq Capital Market to the OTCQX market. This move follows a failure to meet the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)).
🚩 Red Flags
- Delisting from Nasdaq Capital Market.
- Failure to meet minimum stockholders' equity requirements (Rule 5550(b)(1)).
- Transitioning to OTCQX often results in reduced liquidity and higher volatility.
- The company was already under a Nasdaq Panel Monitor prior to this decision.
📋 Key Facts
- Company will withdraw from the Nasdaq hearings process effective May 24, 2024.
- Shares are expected to be suspended from trading on Nasdaq at the opening of trading on Wednesday, May 29, 2024.
- The company intends to transition its listing to the OTCQX market under the same symbol 'MRAI'.
- Delisting is due to non-compliance with minimum stockholders' equity requirements (Nasdaq Listing Rule 5550(b)(1)).
- The company expects delisting will reduce costs as it pursues a strategy for profitable growth.
Marpai, Inc. announced the immediate resignation of Mike Dendy from its Board of Directors on May 12, 2024. The company explicitly stated that the resignation was not due to any disagreements regarding operations, policies, or practices.
📋 Key Facts
- Mike Dendy resigned from the Board of Directors effective May 12, 2024.
- The resignation was voluntary and not related to any disagreement with the Company's operations, policies, or practices.
Marpai, Inc. filed an 8-K to announce the release of selected financial information for the three months ended March 31, 2024. The filing serves as a formal notification that earnings/financial results have been made public via press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Three months ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing selected financial information.
- Company is an emerging growth company.
Marpai, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 6, 2024. The meeting included the election of directors and approval of several key corporate matters, including a new stock incentive plan.
🚩 Red Flags
- Approval of blank-check preferred stock can potentially be used for defensive measures or dilutive financing, though this is standard corporate practice.
📋 Key Facts
- Stockholders approved the 2024 Global Stock Incentive Plan (Proposal No. 2).
- Eight directors were elected to hold office until the next annual meeting: Damien Lamendola, Yaron Eitan, Mike Dendy, Sagiv Shiv, Mohsen Moazami, Colleen DiClaudio, Jennifer Calabrese, and Robert Pons.
- Stockholders ratified the appointment of UHY LLP as the independent registered public accounting firm for fiscal year 2024 (Proposal No. 3).
- Stockholders approved an amendment to the Certificate of Incorporation to include 2,000,000 shares of blank-check preferred stock (Proposal No. 4).
Marpai, Inc. entered into a $11.83 million Senior Secured Convertible Debenture agreement on April 15, 2024. The deal includes significant personal guarantees from the CEO and restrictive covenants.
🚩 Red Flags
- High-interest rate (Prime + 5.75%) indicating high risk profile for the issuer.
- Personal guarantees from the CEO (Damien Lamendola) and his controlled entity (Hillcour Holding, LLC).
- Restrictive covenants: Limits on incurring debt, creating liens, amending bylaws, or selling assets.
- Liquidated damages clause in the Registration Rights Agreement if registration deadlines are missed.
- Senior secured status gives lenders first priority over company assets.
📋 Key Facts
- Aggregate principal amount of $11,830,000 in Senior Secured Convertible Debentures.
- Total purchase price of $11,000,000 (discounted).
- Interest rate: Prime interest rate + 5.75% per annum.
- Monthly principal payments of $140,000 starting October 15, 2024.
- Maturity date set for April 15, 2027.
- Conversion price: $3.00 per share (floor at $2.23).
- Security: First priority liens on certain assets via JGB Collateral LLC.
- Guarantors include CEO Damien Lamendola and Hillcour Holding, LLC.
Marpai, Inc. filed an 8-K to announce the release of selected financial information for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of quarterly and annual financial results (Item 2.02).
- Reporting period covers the three months and full year ended December 31, 2023.
- The company is an emerging growth company.
Marpai, Inc. announced that it has received an extension from a Nasdaq panel to comply with continued listing requirements. This follows a period of non-compliance regarding Nasdaq's minimum standards.
🚩 Red Flags
- Delisting risk: The company was previously in non-compliance with Nasdaq's continued listing requirements.
- Regulatory uncertainty: While an extension was granted, the company remains at risk of delisting if compliance is not achieved within the new timeframe.
📋 Key Facts
- The company issued a press release on March 13, 2024, regarding the Nasdaq panel decision.
- Nasdaq has granted Marpai, Inc. an extension to comply with continued listing requirements.
- The filing is categorized under Item 8.01 (Other Events).
Marpai, Inc. entered into a Securities Purchase Agreement with HillCour Investment Fund, LLC to issue 910,000 shares of Class A common stock at $1.65 per share. The purchasing entity is controlled by the Company's CEO, Damien Lamendola.
🚩 Red Flags
- Related-party transaction: The securities are being sold to an entity controlled by the CEO.
- Potential dilution: Issuance of 910,000 new shares in a private placement.
📋 Key Facts
- Date of agreement: March 7, 2024
- Issuer: Marpai, Inc.
- Purchaser: HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola)
- Security type: Class A common stock
- Quantity: 910,000 shares
- Price per share: $1.65 (or the Nasdaq consolidated closing bid price as of March 7, 2024)
Marpai, Inc. issued an 8-K to provide preliminary unaudited financial information for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is an amendment (8-K/A) regarding results of operations and financial condition.
- Preliminary unaudited financial information was released via press release on March 6, 2024.
- Reporting period covers the three months and full year ended December 31, 2023.
Marpai, Inc. issued a press release containing preliminary unaudited financial information for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is an Item 8.01 (Other Events) disclosure.
- Company released selected preliminary unaudited financial results for Q4 and FY 2023 on March 6, 2024.
- Financial information covers the period ending December 31, 2023.
Marpai, Inc. issued an 8-K to announce a new client agreement via a press release. The filing does not disclose specific financial terms or the identity of the client within the text provided.
🚩 Red Flags
- Lack of material financial details regarding the agreement within the 8-K filing itself.
📋 Key Facts
- The company issued a press release titled 'Marpai Announces Off-Cycle New Client Agreement' on March 5, 2024.
- The announcement is filed under Item 8.01 (Other Events).
- No specific revenue figures or contract durations were disclosed in the 8-K text.
Marpai, Inc. entered into two significant financial agreements: an amendment to a prior purchase agreement with AXA S.A. involving contingent price reductions and deferred payments, and a sale of future receipts to Libertas Funding LLC for $1.7 million.
🚩 Red Flags
- Related-party transaction: CEO Damien Lamendola personally guaranteed the Libertas Funding agreement via entities he controls.
- Liquidity pressure: The company is selling future receipts at a significant discount ($1.7M for $2.193M in receivables) to raise immediate cash.
- Contingent liabilities: Significant annual payment obligations to AXA ranging from ~$2.3M up to $25.3M depending on meeting criteria.
- Dependency on largest shareholder: The ability to reduce purchase price is contingent upon a $3M equity contribution by the largest shareholder.
📋 Key Facts
- Entered into Amendment No. 1 to Purchase Agreement with AXA S.A. on February 7, 2024.
- AXA Amendment allows for a $3M reduction in the Base Purchase Price if specific 'Reduction Criteria' are met by Dec 31, 2024 (including a $3M equity contribution from the largest shareholder and maintaining Nasdaq listing).
- The AXA Amendment defers certain net proceeds payments to AXA until January 15, 2025, or December 31, 2025, for private offerings by officers/directors.
- Entered into an Agreement of Sale of Future Receipts with Libertas Funding LLC on February 5, 2024.
- Libertas agreement involves selling $2.193M in future receipts for a purchase price of $1.7M over nine months.
- CEO Damien Lamendola provided a personal guarantee for the Libertas funding through entities he controls.
Marpai, Inc. announced a significant management restructuring involving the appointment of John Powers as President and COO, alongside new employment agreements for the CEO and CFO. Concurrently, the company's existing COO, Gonen Antebi, resigned and entered into a separation and consulting agreement.
🚩 Red Flags
- Management turnover: Departure of the current COO (Gonen Antebi) immediately following new executive appointments.
- Significant equity dilution potential via large RSU grants to incoming/existing executives and warrants for departing officer.
- Low cash compensation for CEO ($1.00 salary) and CFO ($35,568 salary) may indicate liquidity constraints or a focus on equity-based incentives.
📋 Key Facts
- John Powers appointed as President and COO effective Jan 2, 2024; annual salary $150,000 plus RSUs (150,000 shares).
- CEO Damien Lamendola entered a new employment agreement with an annual salary of $1.00 and 600,000 RSUs.
- CFO Steve Johnson entered a new employment agreement with an annual salary of $35,568 and 350,000 RSUs.
- COO Gonen Antebi resigned effective Jan 24, 2024; granted a warrant for up to 130,000 shares at $2.50/share.
- Gonen Antebi entered a consulting agreement starting Feb 1, 2024, with a $5,000 monthly retainer through Nov 30, 2024.
Marpai, Inc. entered into a Securities Purchase Agreement with HillCour Investment Fund, LLC, an entity controlled by the CEO and Chairman, to issue 1,322,100 shares of Class A common stock at $0.9201 per share.
🚩 Red Flags
- Related-party transaction involving the CEO, Chairman, and a Director
- Private placement to insiders may indicate difficulty in raising capital from external third parties
- Potential dilution for existing non-insider shareholders
📋 Key Facts
- Date of agreement: January 16, 2024
- Issuer: Marpai, Inc.
- Purchaser: HillCour Investment Fund, LLC (controlled by CEO Damien Lamendola, Chairman Yaron Eitan, and Director Robert Pons)
- Securities issued: 1,322,100 shares of Class A common stock
- Price per share: $0.9201 (based on the consolidated closing bid price on Nasdaq as of Jan 16, 2024)
- Total transaction value: Approximately $1,216,587